Eli Lilly and Company (NYSE:LLY) is included among the 12 Best Stocks to Buy for the Long Term. Eli Lilly (LLY) Taps Gene-Editing Technology to Target Hearing Loss, Reuters Reports According to a report by Reuters, Eli Lilly and Company (NYSE:LLY) has signed an agreement worth up to $1.12 billion with Seamless Therapeutics. The Germany-based startup announced the deal on January 28. The partnership focuses on developing and commercializing treatments for hearing loss using Seamless’ gene-editing platform ...